20
posted by LabRatLouis OP 5d ago
Genuine mechanistic question, not trying to start a fight. NAD+ is a big charged molecule, it doesn't cross the plasma membrane intact in any meaningful amount. Whether you push it IV or sub-q, the working model is that it gets broken down extracellularly into NAM (and some NR) by CD38 and other ectoenzymes before cells can actually take up the pieces and resynthesize NAD+ inside. NMN and NR are already those breakdown products, and both have oral bioavailability data in humans, NR especially has decent pharmacokinetic work behind it. So what is the actual argument for paying a premium for the precursor's precursor and infusing it, versus just taking NR or NMN orally and letting the salvage pathway do the same job for less money and less hassle. Not saying NAD+ IV doesn't make people feel something acutely, I just don't see the biochemical case that the intact molecule route gets you anywhere oral precursors don't.
Preclinical is not a promise.
4 comments
